JP7781057B2 - Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法 - Google Patents

Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法

Info

Publication number
JP7781057B2
JP7781057B2 JP2022523047A JP2022523047A JP7781057B2 JP 7781057 B2 JP7781057 B2 JP 7781057B2 JP 2022523047 A JP2022523047 A JP 2022523047A JP 2022523047 A JP2022523047 A JP 2022523047A JP 7781057 B2 JP7781057 B2 JP 7781057B2
Authority
JP
Japan
Prior art keywords
raav
irf2bpl
promoter
seq
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552014A (ja
JP2022552014A5 (https=
Inventor
ニコラス セバスティアン ウェイン，
キャスリン クリスティーン マイヤー，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2022552014A publication Critical patent/JP2022552014A/ja
Publication of JP2022552014A5 publication Critical patent/JP2022552014A5/ja
Application granted granted Critical
Publication of JP7781057B2 publication Critical patent/JP7781057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022523047A 2019-10-18 2020-10-19 Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法 Active JP7781057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923432P 2019-10-18 2019-10-18
US62/923,432 2019-10-18
PCT/US2020/056358 WO2021077101A1 (en) 2019-10-18 2020-10-19 Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene

Publications (3)

Publication Number Publication Date
JP2022552014A JP2022552014A (ja) 2022-12-14
JP2022552014A5 JP2022552014A5 (https=) 2023-10-26
JP7781057B2 true JP7781057B2 (ja) 2025-12-05

Family

ID=73402144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523047A Active JP7781057B2 (ja) 2019-10-18 2020-10-19 Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法

Country Status (6)

Country Link
US (1) US12606846B2 (https=)
EP (1) EP4045662A1 (https=)
JP (1) JP7781057B2 (https=)
AU (1) AU2020366242A1 (https=)
CA (1) CA3158131A1 (https=)
WO (1) WO2021077101A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115927664A (zh) * 2022-11-09 2023-04-07 苏州赛美科基因科技有限公司 一种用于快速鉴定irf2bpl突变系斑马鱼基因型的引物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006296346A (ja) 2005-04-22 2006-11-02 Kanazawa Univ 糖尿病の病態と関連して発現変動する遺伝子およびその利用
JP2018500311A (ja) 2014-12-16 2018-01-11 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
WO2018094251A1 (en) 2016-11-17 2018-05-24 Kaspar Brian K Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
JP2019500034A (ja) 2015-12-15 2019-01-10 ジェンザイム・コーポレーション ムコリピドーシスｉｉ型を治療するためのアデノ随伴ウイルスベクター

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2001500497A (ja) 1996-09-06 2001-01-16 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006296346A (ja) 2005-04-22 2006-11-02 Kanazawa Univ 糖尿病の病態と関連して発現変動する遺伝子およびその利用
JP2018500311A (ja) 2014-12-16 2018-01-11 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
JP2019500034A (ja) 2015-12-15 2019-01-10 ジェンザイム・コーポレーション ムコリピドーシスｉｉ型を治療するためのアデノ随伴ウイルスベクター
WO2018094251A1 (en) 2016-11-17 2018-05-24 Kaspar Brian K Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEGER Sabine et al.，"Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis"，THE JOURNAL OF CLINICAL INVESTIGATION，2007年08月01日，Vol.117, No.8，pp.2145-2154，DOI: 10.1172/JCl31752
MARCOGLIESE Paul C. et al.，"IRF2BPL Is Associated with Neurological Phenotypes"，THE AMERICAN JOURNAL OF HUMAN GENETICS，2018年08月01日，Vol.103, No.2，pp.245-260，DOI: 10.1016/j.ajhg.2018.07.006

Also Published As

Publication number Publication date
EP4045662A1 (en) 2022-08-24
US20220389453A1 (en) 2022-12-08
JP2022552014A (ja) 2022-12-14
US12606846B2 (en) 2026-04-21
CA3158131A1 (en) 2021-04-22
WO2021077101A1 (en) 2021-04-22
AU2020366242A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US20250161490A1 (en) Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
US12257317B2 (en) Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
US20230302157A1 (en) Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy
CA3089080A1 (en) Gene therapy for limb-girdle muscular dystrophy type 2c
JP2026009430A (ja) 筋肉疾患の筋肉を標的とするための最適化された遺伝子療法
US20220042045A1 (en) Expression cassettes for gene therapy vectors
KR20240095165A (ko) 근이영양증의 치료
JP2022533645A (ja) グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善
JP7781057B2 (ja) Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法
US20230211018A1 (en) Materials and methods for treatment of disorders associated with the ighmbp2 gene
JP7826334B2 (ja) 髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルス
JP7534961B2 (ja) ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法
EP4198134A1 (en) Gamma-sarcoglycan gene transfer increase using modified itr sequences
JP2026503144A (ja) 発現を調節するための物質及び方法
JP2025524569A (ja) Ｃｌｎ１ポリヌクレオチドのアデノ随伴ウイルス送達
EA052000B1 (ru) Доставка микродистрофина вектором на основе адено-ассоциированного вируса для лечения мышечной дистрофии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251125

R150 Certificate of patent or registration of utility model

Ref document number: 7781057

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150